Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genkyotex SA

Small molecule NOX inhibitors for diabetic neuropathy

This article was originally published in Start Up

Executive Summary

Genkyotex SA, named after Geneva, Kyoto and Texas, the locations of three of the academic founders, is developing small molecules that specifically inhibit NOX enzymes. Its lead product is a selective and orally available NOX1/4 inhibitor and is a first-in-class molecule. The initial target for this product is diabetic nephropathy, but the company believes it has potential in a range of other disorders in areas of unmet medical need, including in atherosclerosis, ophthalmological diseases involving angiogenesis such as retinopathy and wet age-related macular degeneration, and fibrosis. The agent has orphan drug status in the EU and the US for the treatment of idiopathic pulmonary fibrosis.


Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts